KIT and gastrointestinal stromal tumor: Sensitivity of the assay for all known KIT exon 11 mutations in GIST is lower than 95% since the designed assay covers 80% of the described KIT exon 11 mutations (in the described cohort 21/27 mutations were detected resulting in a sensitivity of 77%).